Compare BHRB & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHRB | TRAX |
|---|---|---|
| Founded | 1852 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2023 | 2026 |
| Metric | BHRB | TRAX |
|---|---|---|
| Price | $72.05 | $44.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $80.00 | $74.17 |
| AVG Volume (30 Days) | 132.3K | ★ 1.1M |
| Earning Date | 10-22-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | ★ 173.76 | N/A |
| EPS | ★ 2.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.77 | N/A |
| Revenue Next Year | $11.76 | N/A |
| P/E Ratio | $32.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $58.64 | $15.69 |
| 52 Week High | $75.09 | $49.91 |
| Indicator | BHRB | TRAX |
|---|---|---|
| Relative Strength Index (RSI) | 60.09 | 63.82 |
| Support Level | $70.30 | $40.72 |
| Resistance Level | $73.83 | $48.94 |
| Average True Range (ATR) | 1.57 | 3.07 |
| MACD | 0.25 | 0.91 |
| Stochastic Oscillator | 91.43 | 82.84 |
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.